Literature DB >> 23926301

Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma.

Paola Bonetti1, Monica Testoni, Marta Scandurra, Maurilio Ponzoni, Roberto Piva, Afua A Mensah, Andrea Rinaldi, Ivo Kwee, Maria Grazia Tibiletti, Javeed Iqbal, Timothy C Greiner, Wing-Chung Chan, Gianluca Gaidano, Miguel A Piris, Franco Cavalli, Emanuele Zucca, Giorgio Inghirami, Francesco Bertoni.   

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common form of human lymphoma. DLBCL is a heterogeneous disease characterized by different genetic lesions. We herein report the functional characterization of a recurrent gain mapping on chromosome 11q24.3, found in 23% of 166 DLBCL cases analyzed. The transcription factors ETS1 and FLI1, located within the 11q24.3 region, had significantly higher expression in clinical samples carrying the gain. Functional studies on cell lines showed that ETS1 and FLI1 cooperate in sustaining DLBCL proliferation and viability and regulate genes involved in germinal center differentiation. Taken together, these data identify the 11q24.3 gain as a recurrent lesion in DLBCL leading to ETS1 and FLI1 deregulated expression, which can contribute to the pathogenesis of this disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23926301     DOI: 10.1182/blood-2013-01-475772

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma.

Authors:  Itziar Salaverria; Idoia Martin-Guerrero; Rabea Wagener; Markus Kreuz; Christian W Kohler; Julia Richter; Barbara Pienkowska-Grela; Patrick Adam; Birgit Burkhardt; Alexander Claviez; Christine Damm-Welk; Hans G Drexler; Michael Hummel; Elaine S Jaffe; Ralf Küppers; Christine Lefebvre; Jasmin Lisfeld; Markus Löffler; Roderick A F Macleod; Inga Nagel; Ilske Oschlies; Maciej Rosolowski; Robert B Russell; Grzegorz Rymkiewicz; Detlev Schindler; Matthias Schlesner; René Scholtysik; Carsten Schwaenen; Rainer Spang; Monika Szczepanowski; Lorenz Trümper; Inga Vater; Swen Wessendorf; Wolfram Klapper; Reiner Siebert
Journal:  Blood       Date:  2014-01-07       Impact factor: 22.113

2.  SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.

Authors:  Sai-Wen Tang; Sven Bilke; Liang Cao; Junko Murai; Fabricio G Sousa; Mihoko Yamade; Vinodh Rajapakse; Sudhir Varma; Lee J Helman; Javed Khan; Paul S Meltzer; Yves Pommier
Journal:  Clin Cancer Res       Date:  2015-03-16       Impact factor: 12.531

Review 3.  Genetic lesions in diffuse large B-cell lymphomas.

Authors:  M Testoni; E Zucca; K H Young; F Bertoni
Journal:  Ann Oncol       Date:  2015-01-20       Impact factor: 32.976

Review 4.  Current insights into the role of Fli-1 in hematopoiesis and malignant transformation.

Authors:  Yaacov Ben-David; Babu Gajendran; Klarke M Sample; Eldad Zacksenhaus
Journal:  Cell Mol Life Sci       Date:  2022-02-28       Impact factor: 9.261

5.  Chemical stresses fail to mimic the unfolded protein response resulting from luminal load with unfolded polypeptides.

Authors:  Timothy J Bergmann; Ilaria Fregno; Fiorenza Fumagalli; Andrea Rinaldi; Francesco Bertoni; Paul J Boersema; Paola Picotti; Maurizio Molinari
Journal:  J Biol Chem       Date:  2018-02-16       Impact factor: 5.157

6.  Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.

Authors:  Rosaria Chilà; Alessandra Basana; Monica Lupi; Federica Guffanti; Eugenio Gaudio; Andrea Rinaldi; Luciano Cascione; Valentina Restelli; Chiara Tarantelli; Francesco Bertoni; Giovanna Damia; Laura Carrassa
Journal:  Oncotarget       Date:  2015-02-20

7.  Well-differentiated angiosarcoma of spleen: a teaching case mimicking hemagioma and cytogenetic analysis with array comparative genomic hybridization.

Authors:  Lichen Xu; Yimin Zhang; Hong Zhao; Qingxiao Chen; Weihang Ma; Lanjuan Li
Journal:  World J Surg Oncol       Date:  2015-10-13       Impact factor: 2.754

8.  Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor.

Authors:  Loredana Vesci; Elena Bernasconi; Ferdinando Maria Milazzo; Rita De Santis; Eugenio Gaudio; Ivo Kwee; Andrea Rinaldi; Silvia Pace; Valeria Carollo; Giuseppe Giannini; Francesco Bertoni
Journal:  Oncotarget       Date:  2015-03-20

9.  Synergistic cooperation and crosstalk between MYD88L265P and mutations that dysregulate CD79B and surface IgM.

Authors:  James Q Wang; Yogesh S Jeelall; Peter Humburg; Emma L Batchelor; Sarp M Kaya; Hee Min Yoo; Christopher C Goodnow; Keisuke Horikawa
Journal:  J Exp Med       Date:  2017-07-12       Impact factor: 14.307

10.  The 11q-Gain/Loss Aberration Occurs Recurrently in MYC-Negative Burkitt-like Lymphoma With 11q Aberration, as Well as MYC-Positive Burkitt Lymphoma and MYC-Positive High-Grade B-Cell Lymphoma, NOS.

Authors:  Beata Grygalewicz; Renata Woroniecka; Grzegorz Rymkiewicz; Jolanta Rygier; Klaudia Borkowska; Aleksandra Kotyl; Katarzyna Blachnio; Zbigniew Bystydzienski; Beata Nowakowska; Barbara Pienkowska-Grela
Journal:  Am J Clin Pathol       Date:  2017-12-20       Impact factor: 2.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.